Log in

NYSE:AGNAllergan Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$193.02
0.00 (0.00 %)
(As of 05/8/2020)
Add
Compare
Today's Range
$191.64
Now: $193.02▼
$193.38
50-Day Range
$184.04
MA: $190.89▼
$193.89
52-Week Range
$114.27
Now: $193.02▼
$202.21
Volume12.44 million shs
Average Volume4.01 million shs
Market Capitalization$63.50 billion
P/E RatioN/A
Dividend Yield1.53%
Beta1.2
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Read More
Allergan logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.0Community Rank: 3.3Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:AGN
Previous SymbolNYSE:ACT
CUSIP01849010
CIK1578845
Webwww.allergan.com
Phone862-261-7000

Debt

Debt-to-Equity Ratio0.31
Current Ratio1.01
Quick Ratio0.84

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio11.56
P/E Growth1.63

Sales & Book Value

Annual Sales$16.09 billion
Price / Sales3.95
Cash Flow$36.70 per share
Price / Cash Flow5.26
Book Value$177.28 per share
Price / Book1.09

Profitability

EPS (Most Recent Fiscal Year)$17.64
Net Income$-5,271,000,000.00
Net Margins-15.44%
Return on Equity8.46%
Return on Assets5.31%

Miscellaneous

Employees17,400
Outstanding Shares329,002,000
Market Cap$63.50 billion
Next Earnings DateN/A
OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allergan (NYSE:AGN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Allergan?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Allergan.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) posted its quarterly earnings data on Monday, February, 10th. The company reported $5.22 EPS for the quarter, topping the Zacks' consensus estimate of $4.57 by $0.65. The company had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.29 EPS.
View Allergan's earnings history.

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Wednesday, March 18th. Stockholders of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a dividend yield of 1.53%. The ex-dividend date is Wednesday, April 15th.
View Allergan's dividend history.

How will Allergan's stock buyback program work?

Allergan declared that its board has initiated a stock repurchase plan on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's management believes its stock is undervalued.

What price target have analysts set for AGN?

5 brokers have issued 1-year target prices for Allergan's stock. Their forecasts range from $178.00 to $203.00. On average, they anticipate Allergan's stock price to reach $193.00 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts' price targets for Allergan.

Has Allergan been receiving favorable news coverage?

Media coverage about AGN stock has trended very positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Allergan.

Who are some of Allergan's key competitors?

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
View all competitors.

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Who are Allergan's key executives?

Allergan's management team includes the following people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Who are Allergan's major shareholders?

Allergan's stock is owned by many different retail and institutional investors. Top institutional shareholders include Ashburton Jersey Ltd (0.06%), Cerebellum GP LLC (0.01%) and Valeo Financial Advisors LLC (0.00%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh.
View institutional ownership trends for Allergan.

Which institutional investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC.
View insider buying and selling activity for Allergan.

Which institutional investors are buying Allergan stock?

AGN stock was purchased by a variety of institutional investors in the last quarter, including Ashburton Jersey Ltd, and Cerebellum GP LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh.
View insider buying and selling activity for Allergan.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $193.02.

How big of a company is Allergan?

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

What is Allergan's official website?

The official website for Allergan is www.allergan.com.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.